13125 Berlin, de
+49 (30) 941084-138
Eckert & Ziegler awards prizes for outstanding achievements in nuclear medicine research
The competition, which is run by Eckert & Ziegler AG in cooperation with the EANM and awards prizes of €1,000 each, was held for the sixth time.
A jury of seven EANM members chose the following five laureates from a total of 589 entries:
E. Gourni, Germany: Development and pre-clinical evaluation of a new glucose-dependent insulinotropic polypeptide (GIP) based of a broad spectrum of neuroendocrine tumors
B. Lambert, Belgium: Tc99m labelled S-HYNIC Certolizumab Pegol for selecting patients for anti-TNFα treatment: a biodistribution and dosimetric study
E. Lopci, Italy: PET-guided radiotherapy planning in prostate cancer patients
A. H. Staudacher, Australia: Synergistic anti-cancer response to chemotherapy and 177Lu-labelled APOMAB® radioimmunotherapy in a preclinical model of lung cancer
S. Teixeira, the Netherlands: Evaluation of primary tumour and regional lymph node metastases with FDG PET/CT in breast cancer patients: prone versus supine position
"Some of the previous winners have turned their work into new products. This can be seen, for example, through the establishment of SurgicEye, a company that develops and markets intraoperative and interventional imaging systems, which can be used to safely remove radioactively labeled tumors with minimum damage to surrounding tissue. We are proud that our award has helped patients benefit from new technologies and that knowledge has been transformed into prosperity," said Karolin Riehle, spokesperson at Eckert & Ziegler AG.
The purpose of the Eckert & Ziegler Abstract Award is to help young research scientists present their work on medical imaging to a wide audience.
With around 630 employees, the Berlin-based Eckert & Ziegler AG (ISIN DE0005659700) is one of the world's largest providers of isotope components for radiotherapy and nuclear medicine.
More information on the Eckert & Ziegler Abstract Award is available here: www.ezag.de/de/award_d.html
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to email@example.com.